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Summary
Objective: To compare the effectiveness and safety of repeat treatment with hylan G-F 20 based on data from a randomized, controlled trial
[Raynauld JP, Torrance GW, Band PA, Goldsmith CH, Tugwell P, Walker V, et al. A prospective, randomized, pragmatic, health outcomes trial
evaluating the incorporation of hylan G-F 20 into the treatment paradigm for patients with knee osteoarthritis (Part 1 of 2): clinical results.
Osteoarthritis Cartilage 2002;10:506e17]. The hypotheses tested were whether the single-course and repeat-course subgroups would be
superior to appropriate care and not different from each other.
Method: A total of 255 patients with knee osteoarthritis were randomized to ‘‘appropriate care with hylan G-F 20’’ or ‘‘appropriate care without
hylan G-F 20’’. The hylan G-F 20 group was partitioned into two subgroups: (1) patients who received a single course of hylan G-F 20; and (2)
patients who received two or more courses of hylan G-F 20.
Results: For the primary effectiveness measure, change in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain
score as a percent of baseline, the single-course subgroup improved by 41%, the repeat-course subgroup by 35%, and the appropriate care
group by 14%. Both subgroups improved signiﬁcantly more than the appropriate care group (P! 0.05), and were not statistically signiﬁcantly
different from each other (70% power to detect a 20% difference). Secondary effectiveness measures showed similar results. In the repeat-
course subgroup, no statistically signiﬁcant differences were found in the number of local adverse events, the number of patients with local
adverse events, or arthrocentesis rates between the ﬁrst and repeat courses of treatment.
Conclusions: Although the study was neither designed nor powered to examine repeat treatment, this a posteriori analysis provides support
for a favorable effectiveness and safety proﬁle of hylan G-F 20 in repeat course patients.
ª 2004 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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SocietyIntroduction
Osteoarthritis is a chronic degenerative disease, character-
ized by intermittent periods of pain and disability2. A wide
range of treatment options are included in the 2000
guidelines for the treatment of knee osteoarthritis by the
American College of Rheumatology3. Patients present for
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Received 2 March 2004; revision accepted 22 October 2004.11treatment at different stages of disease and with varying
levels of symptomatology and disability, and therefore,
treatment algorithms must be customized to an individual
patient’s needs. Patient responses to long term and repeat
administration of the available treatment options are also
important factors to consider. Most physicians recognize
that appropriate care often consists of a combination of the
available treatment modalities4.
Viscosupplementation, a local therapy for patients with
knee osteoarthritis in which the synovial ﬂuid is replaced by
intra-articular injections of hyaluronan-based ﬂuids, is
included among the treatment options recommended in
the 2000 American College of Rheumatology guidelines3.
A course of viscosupplementation with hylan G-F 201
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Cambridge, MA, USA), a cross-linked hyaluronan deriva-
tive, consists of a series of three weekly injections, and is
indicated to provide pain relief for up to 6 months5.
However, little information is available regarding patient
outcomes after the administration of repeat courses of hylan
G-F 20. In a retrospective analysis of 336 patients treated
with hylan G-F 20 over a 2-year period in clinical practice,
Lussier et al.6 reported that repeat courses were safe and
effective, with no statistically signiﬁcant differences be-
tween ﬁrst and later courses in either safety or effective-
ness. A second retrospective analysis reported by Leopold
et al.7 found that the prevalence of local reactions to hylan
G-F 20 increased signiﬁcantly when comparing ﬁrst and
second courses in unrelated patient cohorts. To date, no
prospective controlled clinical trials providing data on repeat
courses of hylan G-F 20 have been reported.
To address the need for prospectively collected in-
formation on the safety and effectiveness of repeat courses
of viscosupplementation with hylan G-F 20, the data from
a 1-year prospective, randomized, controlled, health out-
comes trial were analyzed with a speciﬁc focus on patients
who received more than one course of hylan G-F 20.
Because of its pragmatic design, patients in this trial were
permitted by the protocol to receive additional courses of
viscosupplementation as medically required, enabling
a medical assessment of repeat administration. The original
report of this trial demonstrated that hylan G-F 20, when
added to an appropriate care treatment regimen for patients
with knee osteoarthritis, provided clinically important and
statistically signiﬁcant improvements for all primary and
secondary outcome measures1. In the present report we
provide additional analyses of the patients in the trial who
received repeat courses during the 1-year study period, to
evaluate speciﬁcally the effectiveness and safety of repeat
treatment with hylan G-F 20.
Methods
DESIGN
The analyses reported here were performed using the
data collected in a health outcomes trial evaluating
viscosupplementation with hylan G-F 20 when added to
an appropriate care treatment paradigm for patients with
knee osteoarthritis. The trial was designed and managed by
a predominantly academic steering committee according to
published guidelines for pharmacoeconomic outcome tri-
als8. The detailed design of this trial and the primary
analyses of the data have been published elsewhere1.
Brieﬂy, the trial was a multicentre, prospective, randomized,
open-label study of 1-year duration, where patients were
randomized to either ‘‘appropriate care with hylan G-F 20’’
or ‘‘appropriate care without hylan G-F 20’’ (appropriate
care). Appropriate care for knee osteoarthritis was deﬁned
by the 1995 Guidelines for the Medical Management of
Osteoarthritis of the Knee proposed by the American
College of Rheumatology9. Patients in the appropriate care
with hylan G-F 20 group could receive more than one
course of hylan G-F 20 treatment in the study knee (knee
most symptomatic or with the most predominant musculo-
skeletal problem) if medically warranted, and could receive
bilateral treatment if their contralateral knee was affected.
Investigators were advised that retreatment should only be
provided when persistent pain recurs, that a minimum of 4
weeks should be allowed between courses of hylan G-F 20,and that previous research had indicated that the duration
of beneﬁt after one course could vary widely but had
a mean of 8.2 months in the patients who required a second
course6. The protocol did not allow hylan G-F 20 treatment
for osteoarthritis in joints other than the knee. Patients in
this study had symptomatic osteoarthritis (mild to moderate
severity) and had received prior treatment with nonsteroidal
anti-inﬂammatory drugs (NSAIDs) or acetaminophen. Pa-
tients were assessed by the clinical investigator at the
baseline and termination (month 12) visits. Follow-up
assessments were completed by telephone at months 1,
2, 4, 6, 8, 10, and 12. Patients could visit their physician as
required for routine care and management of their
osteoarthritis. The study protocol and informed consent
form were approved by the relevant Ethics Committees for
the sites. Informed consent was obtained from each patient.
ENDPOINTS
The primary measure of effectiveness was the mean
change in the Western Ontario and McMaster Universities
Osteoarthritis Index (WOMAC) Likert 3.0 pain score in the
study knee from baseline to termination. The WOMAC is
a self-administered disease-speciﬁc health-related quality
of life instrument that asked the patient questions concern-
ing his/her study knee10. The WOMAC Likert 3.0 provides
a total score, and scores for three subscales: pain, stiffness,
and physical functioning.
There were also secondary measures of effectiveness.
Two of the secondary effectiveness measures were the
percent of patients improved at termination (compared to
baseline) using different combinations of the WOMAC Likert
3.0 subscales to deﬁne an improved patient as follows: (1)
at least 20% improvement from baseline in the WOMAC
pain score in the study knee; and (2) at least 20%
improvement from baseline in the WOMAC pain score in
the study knee and either at least a 20% improvement from
baseline in function score or stiffness score. Based on
previous research11, a 20% difference between treatment
groups for the primary and secondary measures of
effectiveness was established a priori by the steering
committee and investigators as the minimum clinically
important difference. Disease-speciﬁc health-related quality
of life using the WOMAC and general health-related quality
of life using the Short Form 36 (SF-36)12 were also
measured. The SF-36 provides two composite scales:
aggregate physical component and aggregate mental
component.
SAFETY
An adverse event was deﬁned by the protocol as any
emergent signs, symptoms, or undesirable events that
occur while a patient is using a drug, biological product or
device during the study. All adverse events, whether
considered related to the study treatments or not, were
collected during each telephone interview, during ofﬁce
visits and at any time the patient reported an event to the
investigator. The adverse event information obtained from
the patient included a description of the problem, onset and
stop dates, history, severity, outcome of event and action
taken. The data collected on each adverse event were
reviewed by the investigator during monitoring visits. The
relationship to hylan G-F 20, appropriate care, treatment
administration, or to other products or causes was provided
by the investigator during review of the adverse events. If
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related to hylan G-F 20, it was considered in this report as
related to hylan G-F 20.
A local adverse event was deﬁned during the analysis as
any emergent signs or symptoms occurring in the knee,
whether related to study treatment or not. Local adverse
events were examined in particular detail to evaluate any
differences which might be related to the administration of
repeat courses of hylan G-F 20. To separate clinical
information regarding local reactions to viscosupplementa-
tion from other causes of knee symptoms such as the
patient’s disease status (e.g., an osteoarthritis ﬂare) or an
unrelated cause (e.g., traumatic event), local adverse
events that occurred within 48 h of a hylan G-F 20 injection
were analyzed separately from those that occurred at any
other time in the trial, and are reported here.
STATISTICAL METHODS
Data from the locked study database were analyzed
using SAS version 8.2. Descriptive statistics were provided
for the data items of interest. The secondary analyses were
performed by partitioning the originally randomized hylan
G-F 20 group into two subgroups: (1) patients who received
a single course of hylan G-F 20 in the study knee over the
1-year study (single-course subgroup); and (2) patients who
received two or more courses of hylan G-F 20 in the study
knee over the 1-year study (repeat-course subgroup). Both
subgroups were then compared to each other and to the
group randomized to receive appropriate care. The hypoth-
eses to be tested were whether the single-course subgroup
was superior to the appropriate care group, the repeat-
course subgroup was superior to the appropriate care
group, and whether the single-course subgroup and the
repeat-course subgroup were different from each other.
The primary effectiveness measure was analyzed using
Tukey’s test that controlled for the type 1 experimentwise
error rate alpha (0.05). The secondary effectiveness
measure (percent of patients with study knee improved at
termination since baseline) was analyzed using a general-
ized linear model that controlled for the type 1 experiment-
wise error rate by distributing alpha over all three pairwise
comparisons using the Bonferroni adjustment of alpha/3
(alpha for each pairwise comparisonZ 0.05/3Z 0.0166).
Similarly, the local adverse events were analyzed using
a Bonferroni adjustment (i.e., local adverse events, 0.05/
3Z 0.0166; arthrocentesis, 0.05/4Z 0.0125). Both bino-
mial (percent of patients reporting local adverse events) and
Poisson (number of occurrences of a local adverse event)
models were used. The Fisher’s Exact Test was used
where applicable. The difference in the percent of patients
reporting local adverse events and arthrocenteses in the
ﬁrst and second courses of treatment in the repeat-course
subgroup was analyzed using McNemar’s Test. The
primary and secondary effectiveness analyses were ad-
justed for design variables (baseline value of the variable
being analyzed, site, blocking by site, body mass index, and
baseline WOMAC total score). Because the study was not
powered for these secondary analyses, post-hoc power
calculations were performed to estimate the statistical
power of the analyses presented (to detect at least a 20%
difference between groups) for statistical tests where
statistical signiﬁcance was not attained for the primary
and secondary measures of effectiveness. All patients were
included in the intent-to-treat group for all analyses as
described earlier1. One patient was not included, becausethe patient allocated to receive hylan G-F 20 chose not to
take it after randomization. The hot deck method was used
to impute data for the primary and secondary effectiveness
measures as described earlier1.
Results
PATIENTS
In the trial, 128 patients were randomized to receive
appropriate care and 127 patients were randomized to
receive appropriate care with hylan G-F 20. Of the 127
patients randomized to receive appropriate care with hylan
G-F 20, 45 patients received two courses of hylan G-F 20 in
the study knee and three patients received three courses of
hylan G-F 20. The subgroups to be analyzed were therefore
deﬁned as the single-course subgroup (nZ 78), the repeat-
course subgroup (nZ 48), and the appropriate care group
as originally randomized (nZ 128). A total of 24 patients
dropped out of the study (21 in the appropriate care group,
one randomized to hylan G-F 20 who chose not to take it,
and two in the single-course subgroup).
Of the 48 patients receiving more than one course of
viscosupplementation with hylan G-F 20 in the study knee,
the mean number of days between the ﬁrst and second
course of injections was 217 (approximately 7 months)
(min: approximately 2 months; max: approximately 12
months). Three patients also had a third course of injections
with a mean of 200 days between the second and third
course.
Descriptive statistics comparing the demographics, base-
line disease characteristics and baseline outcome meas-
ures of the subgroups are provided in Tables I and II.
Formal statistical analyses comparing the subgroups were
not performed.
TREATMENT FOR KNEE OSTEOARTHRITIS
A total of 306 hylan G-F 20 injections (234 study knee, 72
contralateral knee) were given to the 78 patients in the
single-course subgroup, and 441 hylan G-F 20 injections
were given to the 48 patients in the repeat-course subgroup
[231 during the ﬁrst course (144 study knee, 87 contralat-
eral knee), 201 during the second course (141 study knee,
60 contralateral knee) and nine during the third course (nine
study knee)]. With respect to the contralateral knee, of the
127 patients randomized to hylan G-F 20, 33 received
a single-course in the other knee, 20 received two or more
courses, and 74 received no hylan G-F 20 injections in the
other knee. The utilization of treatments other than hylan
G-F 20 by these subgroups is presented in Figs. 1 and 2.
With respect to corticosteroid injections in the study knee,
both the single-course and repeat-course subgroups were
signiﬁcantly lower than the appropriate care group (both
P! 0.0001). A similar pattern was observed with respect to
steroid injections to the other knee (single-course vs
appropriate care, PZ 0.0050; repeat-course vs appropriate
care, PZ 0.0013).
Nonsteroidal anti-inﬂammatory drug usage was also
similar in the single-course and repeat-course subgroups,
and again lower than in the appropriate care group (Fig. 2).
The single-course subgroup was statistically signiﬁcantly
lower than the appropriate care group (PZ 0.0142),
however, the repeat-course subgroup was not statistically
signiﬁcantly different from the appropriate care group after
Bonferroni correction (PZ 0.0454) (alpha for each pairwise
comparisonZ 0.05/3Z 0.0166). Use of oral analgesics in
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Demographics and disease status at baseline
Baseline measure Groups
Single-course
nZ 78
Repeat-course
nZ 48
Appropriate care
nZ 128
Mean (SD) Mean (SD) Mean (SD)
Age (years) 63.8 (9.5) 60.8 (9.2) 63.5 (10.5)
Body mass index (kg/m2) 31.8 (7.6) 32.8 (8.8) 32.9 (7.2)
Duration (years) of osteoarthritis symptoms
Study knee 9.3 (10.6) 8.7 (7.6) 9.9 (9.7)
Other knee 7.5 (9.9) 7.1 (7.3) 8.3 (9.3)
n (%) n (%) n (%)
Sex: female 52 (66.7) 34 (70.8) 93 (72.7)
Previous therapy for osteoarthritis of the knee(s)
Acetaminophen 57 (73.1) 42 (87.5) 109 (85.2)
NSAIDs 73 (93.6) 46 (95.8) 110 (85.9)
Prior surgery, study knee 22 (28.2) 18 (37.5) 39 (30.5)
Prior surgery, other knee 15 (19.2) 12 (25.0) 23 (18.0)
Radiology grading within 1 year (central gradingy)
Not reported 1 (0.8)
Grade 0 3 (3.9) 1 (2.1) 4 (3.1)
Grade I 12 (15.4) 5 (10.4) 11 (8.6)
Grade II 22 (28.2) 9 (18.8) 33 (25.8)
Grade III 26 (33.3) 23 (47.9) 37 (28.9)
Grade IV 15 (19.2) 10 (20.8) 42 (32.8)
Osteoarthritis at baseline
Other knee affected 65 (83.3) 43 (89.6) 108 (84.4)
Other knee requires treatment 35 (44.9) 32 (66.7) 71 (55.5)
Other joints affected 58 (74.4) 36 (75.0) 87 (68.0)
SDZStandard deviation, NSAIDsZ nonsteroidal anti-inﬂammatory drugs.
yRadiology grading is based on central grading, which may have differed from the site investigator’s determination for patient eligibility.the repeat-course subgroup was higher than in the single-
course subgroup and approached the usage level in the
appropriate care group, however, after the Bonferroni
adjustment, none of the groups were statistically signiﬁ-
cantly different from each other.
EFFECTIVENESS
The results for the primary effectiveness measure and the
two study deﬁnitions of improved patients are provided in
Table III. In all cases the single-course subgroup and the
repeat-course subgroup are similar to each other and better
than the appropriate care group. The incremental difference
between the appropriate care group and either hylan G-F 20
subgroup always exceeded the required 20% difference
established a priori as the minimum clinically important
difference between groups. The differences were statisti-
cally signiﬁcant at the 0.05 level for the primary effective-ness measure. The differences were statistically signiﬁcant
at the 0.0166 level for the deﬁnitions of patient improved
(adjusted using the Bonferroni correction), except for the
difference between the repeat-course subgroup and the
appropriate care group for the second deﬁnition of patient
improved (PZ 0.0181). The differences between the
single-course and the repeat-course subgroups were not
statistically signiﬁcant and there was a 70% power to detect
a minimum clinically important difference of 20%.
All other secondary effectiveness measures, including
the global assessments (Fig. 3) and WOMAC and Short
Form 36 physical component (Table IV) showed a similar
pattern of results favoring both hylan G-F 20 subgroups
over the appropriate care group, and ﬁnding no meaningful
differences between the two hylan G-F 20 subgroups.
The differences between baseline and month 12 provided
in the tables are reﬂective of patient outcomes throughout the
study year, as shown in Fig. 4 for the WOMAC pain score.Table II
WOMAC and SF-36 at baseline
Baseline measure Groups
Single-course nZ 78, Repeat-course nZ 48, Appropriate care nZ 128,
Mean (SD) Mean (SD) Mean (SD)
WOMAC Pain (0 to 20)y 11.0 (2.9) 11.8 (2.3) 11.9 (2.9)
WOMAC Stiffness (0 to 8)y 4.8 (1.4) 5.5 (1.6) 5.1 (1.4)
WOMAC Physical Function (0 to 68)y 38.3 (9.1) 41.4 (9.4) 40.2 (9.3)
SF-36 Physical Component (2 to 76)z 29.3 (6.8) 27.0 (6.0) 28.2 (7.8)
SF-36 Mental Component (2 to 81)z 51.9 (11.4) 51.5 (12.7) 49.9 (11.8)
WOMACZWestern Ontario and McMaster Universities Osteoarthritis Index, SDZ standard deviation, SF-36ZShort Form 36.
yThe higher the score, the worse the problem.
zThe higher the score, the better the health perception.
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There was no statistically signiﬁcant difference in the
percent of patients reporting local adverse events between
the single-course subgroup (19 of 78 patients, 24%) and the
ﬁrst course of treatment in the repeat-course subgroup (11
of 48 patients, 23%) (PZ 0.9943, logistic analysis), or
between the ﬁrst (11 of 48 patients, 23%) and second (13 of
48 patients, 27%) courses of treatment in the repeat-course
subgroup (PZ 0.5930, McNemar’s Test) (Table V). The
number of local adverse events reported were also
compared using Poisson regression, and no signiﬁcant
difference was found between the single-course subgroup
and the ﬁrst course of treatment in the repeat-course
subgroup (PZ 0.3646), as well as between the ﬁrst course
of treatment and the second course of treatment of the
repeat-course subgroup (PZ 0.8728) (Table V). None of
the local adverse events were characterized as serious,
and generally they required minimal intervention (rest, ice
packs, oral analgesic or anti-inﬂammatory medication).
The rate of intra-articular intervention after local reaction
(arthrocentesis with or without steroid injection) was
compared between the single-course and repeat-course
subgroups (unmatched analyses), as well as within the
repeat-course subgroup (matched analysis). There was no
statistically signiﬁcant difference in the number of patients
reporting arthrocentesis between the single-course sub-
group (0 of 78 patients) and the ﬁrst course of treatment in
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Fig. 1. Percent of patients reporting corticosteroid injections in the
study knee and other knee.the repeat-course subgroup (1 of 48 patients) (PZ 0.3810,
Fisher’s Exact), or between the single-course subgroup (0
of 78 patients) and the second course of treatment in the
repeat-course subgroup (4 of 48 patients) (PZ 0.0194,
Fisher’s Exact) after Bonferroni correction (alpha for each
pairwise comparisonZ 0.05/4Z 0.0125). When consider-
ing the number of patients with arthrocentesis in the single-
course subgroup (0 of 78 patients) and the repeat-course
subgroup (during ﬁrst or second course) (5 of 48 patients),
the difference was statistically signiﬁcant (PZ 0.0070,
Fisher’s Exact). However, within the repeat-course sub-
group (matched analysis), no signiﬁcant difference was
found between the ﬁrst course of treatment (1 of 48
patients) and the second course of treatment (4 of 48
patients) (PZ 0.1797, McNemar’s Test).
The majority of the local adverse events were attributed
by the investigators to the injection procedure itself (Table
V). Local adverse events were attributed to hylan G-F 20 for
one patient in the single-course subgroup and for ﬁve
patients in the repeat-course subgroup (two during the ﬁrst
course and three during the second course). Combining the
two subgroups to compare ﬁrst and second courses with
respect to the frequency of local reactions attributed to
hylan G-F 20 on a per injection basis, nine events (in three
patients) were attributed to hylan G-F 20 during the ﬁrst
course (1.7% of 537 injections), and six events (in three
patients) were attributed to hylan G-F 20 during adminis-
tration of second or third courses (2.9% of 210 injections).
There were two events (in two patients) attributed to hylan
G-F 20 and characterized as severe during the administra-
tion of a second or third course (1% of 210 injections).
It should be noted that a single patient reported a fever
associated with a local adverse event attributed by the
investigator to the hylan G-F 20 injection procedure. The
fever occurred after the second injection of a second course
(administered 3 months after the ﬁrst course), and was not
associated with any other signs or symptoms. The fever
resolved in 1 day and the patient completed the trial,
receiving no additional injections of hylan G-F 20, and
reporting additional adverse events in the same knee 6 and
8 months later, and adverse events characterized as
osteoarthritis in both hips, none of which were attributed
by the investigator to hylan G-F 20.
Discussion
The analyses presented here provide new information on
the effectiveness and safety of repeat courses of viscosup-30
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Fig. 2. Percent of patients reporting medications for knee osteoarthritis (any knee); NSAIDsZ nonsteroidal anti-inﬂammatory drugs.
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Primary effectiveness and study definition of improved patients: subgroup results and differences between subgroups
Single-course
nZ 78
Repeat-course
nZ 48
Appropriate care
nZ 127
Between group
change
Primary effectiveness
Change from baseline to termination
in WOMAC pain, meany
4.4 4.4 1.8
Change as a % of baseline, meany 41.3 34.8 13.8
(Single-course) (Repeat-course) 6.5 (PZ 0.6593)
(Single-course) (Appropriate care) 27.5 (P! 0.0001z)
(Repeat-course) (Appropriate care) 21.0 (PZ 0.0042z)
Secondary effectiveness
Patients improved at termination
since baseline
WOMAC Pain 72% 65% 40%
(Single-course) (Repeat-course) 7% (PZ 0.4898)
(Single-course) (Appropriate care) 32% (PZ 0.0001x)
(Repeat-course) (Appropriate care) 24% (PZ 0.0059x)
WOMAC pain and either stiffness or
physical functioning
65% 58% 35%
(Single-course) (Repeat-course) 7% (PZ 0.2718)
(Single-course) (Appropriate care) 30% (PZ 0.0001x)
(Repeat-course) (Appropriate care) 23% (PZ 0.0181)
WOMACZWestern Ontario and McMaster Universities Osteoarthritis Index.
yMean change and percent change were calculated on individual patient basis.
zP! 0.05 using Tukey’s test.
xP! 0.05/3Z 0.0166 adjustment for three comparisons for patient improved.plementation with hylan G-F 20. They include (previously
unreported) data on the percent of patients receiving more
than one course of hylan G-F 20 during a 1-year period and
detailed outcome data speciﬁc to this patient subgroup. In
addition, statistical tests, speciﬁed a posteriori, were
performed to compare the single-course and repeat-course
subgroups to each other and to the group randomized to
receive only appropriate care. Because the data were
collected as part of a prospective, randomized clinical trial,
they include protocol-scheduled measurement of patient
status and utilized validated instruments to quantify
disease-speciﬁc outcomes, general health outcomes andhealth-related quality of life. Safety was evaluated by query-
based collection of adverse events.
During the 1-year study period, 48 of 126 patients (38%)
receiving their ﬁrst course of hylan G-F 20 at baseline
required repeat administration of additional courses to the
study knee at some time during the 1-year study period (the
repeat-course subgroup). In comparison to the appropriate
care group, both the single- and repeat-course subgroups
had greater improvement in the WOMAC and SF-36
physical aggregate scores, which were statistically signiﬁ-
cant and clinically important for the WOMAC. When
comparing the single-course subgroup to the repeat-course72
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Fig. 3. Patient global assessment of change since baseline (percent of patients who improved markedly, moderately and slightly combined).
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Health-related quality of life scores for WOMAC and SF-36
ny Change as a % of baseline P-value (Tukey’s test)
WOMAC Pain (0 to 20)z
Single-course 78 40.2
Repeat-course 48 35.9
Appropriate care 128 13.3
(Single-course) (Repeat-course) 4.3 PZ 0.659
(Single-course) (Appropriate care) 26.9 P! 0.001
(Repeat-course) (Appropriate care) 22.6 PZ 0.004
WOMAC Stiffness (0 to 8)z
Single-course 78 35.8
Repeat-course 48 33.0
Appropriate care 128 10.4
(Single-course) (Repeat-course) 2.8 PZ 0.325
(Single-course) (Appropriate care) 25.4 P! 0.001
(Repeat-course) (Appropriate care) 22.6 PZ 0.026
WOMAC Physical Function (0 to 68)z
Single-course 78 39.6
Repeat-course 48 35.0
Appropriate care 128 14.5
(Single-course) (Repeat-course) 4.5 PZ 0.644
(Single-course) (Appropriate care) 25.1 P! 0.001
(Repeat-course) (Appropriate care) 20.5 PZ 0.002
SF-36 Aggregate Physical (2 to 76)z
Single-course 78 19.7
Repeat-course 48 21.3
Appropriate care 128 1.1
(Single-course) (Repeat-course) 1.6 PZ 0.884
(Single-course) (Appropriate care) 18.6 PZ 0.003
(Repeat-course) (Appropriate care) 20.2 PZ 0.002
SF-36 Aggregate Mental (2 to 81)x
Single-course 78 9.8
Repeat-course 48 14.3
Appropriate care 128 5.4
(Single-course) (Repeat-course) 4.5 PZ 0.821
(Single-course) (Appropriate care) 4.4 PZ 0.214
(Repeat-course) (Appropriate care) 8.9 PZ 0.084
WOMACZWestern Ontario and McMaster Universities Osteoarthritis Index, SF-36ZShort Form 36.
yDue to differences in sample size from baseline to month 12 computation of change (month 12 e baseline) was calculated for patients with
both baseline and termination values. Mean change and percent change were calculated on individual patient basis. At month 12, single-
course, nZ 76 and appropriate care, nZ 107, except for WOMAC pain where imputation was performed.
zThe higher the score, the worse the problem.
xThe higher the score, the better the health perception.subgroup, there were no signiﬁcant differences in effective-
ness and health-related quality of life outcomes. These
analyses suggest that in patients requiring repeat treatment
during a 1-year period, viscosupplementation with hylan
G-F 20 in both single- and repeat-courses is more effective
than treatment with appropriate care alone.
The analyses presented here also provide detailed
information on the safety of repeat courses of hylan G-F
20, including adverse event reports detailing all signs,
symptoms, and medical occurrences observed and re-
ported during the trial whether or not attributable to study
treatment. No evidence of systemic reactions to hylan G-F
20 were observed in either the single-course or repeat-
course subgroups, with the exception of a single patient
reporting a fever of 1-day duration associated with a local
reaction to a hylan G-F 20 injection administered during the
patient’s second course of treatment.
The prevalence of local adverse events occurring within
48 h of hylan G-F 20 injection, whether or not attributed to
hylan G-F 20, was similar during the administration of ﬁrst
and second courses. In the repeat-course subgroup, no
statistically signiﬁcant differences were found in the number
of local adverse events or the number of patients with localadverse events between the ﬁrst and repeat courses. In the
single-course subgroup, one of 78 patients (1%) reported
a local adverse event related to hylan G-F 20. In the repeat-
course subgroup, two of 48 patients (4%) reported hylan G-
F 20-related local events during the ﬁrst course and three of
48 patients (6%) during the second course.
To address the issue of safety while repeating hylan G-F
20 injections over time, the rate of arthrocenteses
performed throughout the study was used as one indicator
of the severity of local adverse events attributed to these
injections. Five of 48 patients within the repeat-course
subgroup, had an arthrocentesis within 48 h of one of the
injections compared to none of the 78 patients within the
single-course subgroup (PZ 0.0070). In contrast, when
evaluating the 48 patients within the repeat-course sub-
group, no signiﬁcant differences were found in arthrocent-
esis rates between the ﬁrst (1 of 48 patients) and second (4
of 48 patients) courses of treatment (PZ 0.1797).
Given that the total number of these arthrocenteses is
small, one patient can greatly affect the signiﬁcance of the
results. Indeed in the repeat-course subgroup, one patient
actually experienced the arthrocentesis during the ﬁrst
course, but not during the second course. It is important in
118 J. P. Raynauld et al.: Hylan G-F 20 e Repeat coursesinterpreting these analyses to note that the repeat-course
subgroup was not deﬁned by randomization, but rather was
self-selected. Therefore, the differential rate of the arthro-
centeses in the repeat-course subgroup vs single-course
subgroup may reﬂect the inﬂuence of patient related
variables, possibly associated with more severe disease
course and susceptibility to ﬂare, rather than being in-
tervention-related. Given the self-selection, we believe that
the within-subgroup comparison is more relevant than the
between-subgroup analysis when a physician is consider-
ing a second course. Moreover, in interpreting the
arthrocentesis results it is important to appreciate that the
criteria for performing an arthrocentesis procedure were not
speciﬁcally deﬁned in the research protocol, but resulted
from individual patientephysician interactions. Given the
demonstrable clinical beneﬁt of adding hylan G-F 20 to the
Appropriate Care program, and the absence of statistically
detectable between-course differences in the number of
local adverse events, the number of patients with local
adverse events, or arthrocentesis rates, in the repeat
treatment subgroup, the beneﬁt (reduction in symptom
severity) to risk (local reaction) ratio remains favorable for
repeat course patients.
Our results generally agree with those reported by
Lussier et al.6 showing no increase in prevalence of local
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Fig. 4. Western Ontario and McMaster Universities Osteoarthritis
Index (WOMAC) pain scores during study year (higher scoreZ
more pain; no imputation).adverse events between the ﬁrst course (7.4%, 25/336
patients) and the second course (7.3%, 3/41). However,
they do differ from the ﬁndings of Leopold et al.7, who
reported that the number of patients reporting a local
adverse event related to hylan G-F 20 increased from 2% (1
in 42 patients) to 21% (4 in 19 patients) comparing ﬁrst and
repeat courses, a difference reported as statistically
signiﬁcant. However the report by Leopold et al. compares
unrelated patient cohorts: a single-course cohort treated
with hylan as part of a clinical trial, and a repeat-course
cohort identiﬁed by retrospective chart review of a clinical
practice database. No information was provided by these
authors regarding the repeat treatment cohort’s response to
their ﬁrst course of treatment in terms of either safety or
effectiveness. This use of an unrelated cohort by Leopold
et al. as the single-course comparator highlights the
difﬁculty in interpreting analyses comparing non-random-
ized or otherwise unrelated patient cohorts.
Several limitations of our analyses should be noted. The
analyses were designed a posteriori. Though this factor
has been taken into account using post-hoc power
calculations, the limitations inherent to all secondary
analyses remain. The study, like most clinical trials, was
also not powered to detect rare safety events. In addition,
the single- and repeat-course subgroups were not de-
termined by randomization, and therefore may be dissimilar
with regard to measured and unmeasured baseline disease
characteristics (e.g., disease severity) (Tables I and II). The
ﬁndings may also be susceptible to selection bias since
there were no pre-established rigorous criteria for patients
to receive repeat courses of hylan G-F 20. On the other
hand, the selection for repeat treatment in this trial is likely
to mimic selection in naturalistic settings, and accordingly
the results reported here are directly relevant to actual
clinical practice. Finally, the effect of hylan G-F 20 was not
evaluated in the contralateral knee given that the primary
focus of this study was on the most problematic knee. The
impact of hylan G-F 20 on the contralateral knee is thus
unknown.
The need for therapies that are safe and effective for the
long-term management of patients with knee osteoarthritis
symptoms is widely acknowledged. Though it is challenging
to conduct classical clinical trials that address long-term
outcomes and repeat administration, these issues can be
practically addressed using pragmatic trial designs that
provide information particularly relevant to real world
situations. Using data collected in a prospective, random-
ized, pragmatic trial, the analyses reported here provide
support for the effectiveness and safety of viscosupple-
mentation with hylan G-F 20 in patients requiring repeat
treatment during a 1-year period.Table V
Investigator attribution of local adverse events occurring within 48 h of a hylan G-F 20 injection
Relatedness Single-course (n = 78) Repeat-course (n = 48)
First course Second course
No of adverse events (No of patients)
Hylan G-F 20 related (remotely, possibly, probably) 6 (1) 3 (2) 6 (3)
Injection procedure related 33 (17) 15 (7) 9 (6)
Disease related 0 (0) 1 (1) 0 (0)
Unrelated 2 (2) 1 (1) 6 (5)
Total 41 (19) 20 (11) 21 (13)
Data include study knee and other knee. The total number of patients listed in the last row can be less than the addition of patients listed
within each row, because the options for relatedness are not mutually exclusive.
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